Similares a Mepolizumab Add-On Reduces COPD Exacerbations in Triple-Therapy Patients | ATS 2026

20 vecinos (text_768) · 1.2K views · HCPLive · Estados Unidos


★	Mepolizumab Add-On Reduces COPD Exacerbations in Triple-Therapy Patients \| ATS 2026	HCPLive @hcplivenews	1.2K	Estados Unidos
15	Efdoralprin Alfa Normalizes Alpha-1 Antitrypsin Levels I #ats2026	HCPLive @hcplivenews	548	Estados Unidos	85
16	La Universitat se suma al Dia Europeu de Dèficit d'Alfa-1	Universitat de València @universitatvalencia	481	España	85
20	Potential Biomarker to Identify Pregnant Women at Greater Risk for #Asthma Exacerbations I ATS 2026	HCPLive @hcplivenews	453	Estados Unidos	84
17	Inhaled Treprostinil for IPF: TETON-1 Phase 3 Results With Steven Nathan, MD \| ATS 2026	HCPLive @hcplivenews	301	Estados Unidos	85
4	Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus F. Rabe, MD, PhD	HCPLive @hcplivenews	198	Estados Unidos	88
18	William Feldman, MD: Azithromycin Over Roflumilast in Real World COPD Data	HCPLive @hcplivenews	182	Estados Unidos	85
14	Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results	HCPLive @hcplivenews	156	Estados Unidos	86
5	Tezepelumab Reduced Severe Asthma Exacerbations Across Phenotypes \| ATS 2026	HCPLive @hcplivenews	122	Estados Unidos	88
19	Phase 3b ENCORE: ALIS Improves MAC Lung Disease Outcomes \| ATS 2026	HCPLive @hcplivenews	117	Estados Unidos	84
1	Mepolizumab Reduced COPD Hospitalizations in Eosinophilic Disease \| ATS 2026 With Gerard Criner, MD	HCPLive @hcplivenews	113	Estados Unidos	95
6	AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD	HCPLive @hcplivenews	105	Estados Unidos	88
12	Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results	HCPLive @hcplivenews	82	Estados Unidos	86
10	SUNRISE: Tezepelumab Shows Meaningful OCS Reduction in Severe Asthma	HCPLive @hcplivenews	78	Estados Unidos	86
7	Dupilumab Doubled Asthma Remission Odds in Type 2 Asthma:	HCPLive @hcplivenews	71	Estados Unidos	88
8	ATS 2026 Asthma Updates: Tezepelumab, Dupilumab, OCS Reduction & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	70	Estados Unidos	87
3	Tezepelumab Cuts Severe Asthma Exacerbations 70% in Real-World Patients \| ATS 2026	HCPLive @hcplivenews	68	Estados Unidos	88
11	Can CSU Patients Achieve True Remission? BTK Inhibitors, Biomarker Barriers, & More \| EAC 2026	HCPLive @hcplivenews	58	Estados Unidos	86
13	ATS 2026 Pulmonology: AD109, Ralinepag, ALIS, Itepekimab & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	55	Estados Unidos	86
9	SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026	HCPLive @hcplivenews	48	Estados Unidos	87
2	Pegtarazimod Cuts Oxygen Need in Hospitalized COPD Patients \| ATS 2026 \| Gerald Criner, MD	HCPLive @hcplivenews	29	Estados Unidos	88